Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid:
A randomised controlled pilot trial
Article first published online: 3 OCT 2005
Volume 26, Issue 1, pages 46–54, February 2006
How to Cite
Moreau, R., Valla, D.-C., Durand-Zaleski, I., Bronowicki, J.-P., Durand, F., Chaput, J.-C., Dadamessi, I., Silvain, C., Bonny, C., Oberti, F., Gournay, J., Lebrec, D., Grouin, J.-M., Guémas, E., Golly, D., Padrazzi, B. and Tellier, Z. (2006), Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid:. Liver International, 26: 46–54. doi: 10.1111/j.1478-3231.2005.01188.x
- Issue published online: 31 OCT 2005
- Article first published online: 3 OCT 2005
- Received 1 April 2005, accepted 12 July 2005
- cost analysis;
- plasma expander
Abstract: Background: The question of which colloid (albumin or synthetic colloids) used for plasma expansion following paracentesis or other complications requiring fluid loading in patients with cirrhosis remains controversial.
Aims: To compare outcome and hospital-related cost in patients with cirrhosis treated with 20% human albumin with those treated with a synthetic colloid (3.5% polygeline).
Methods: The primary end point was occurrence of a first liver-related complication.
Results: When the trial was prematurely discontinued because of safety concerns about bovine-derived products, 30 patients were assigned to receive albumin and 38 were assigned to receive a synthetic colloid. Sixty-three patients were included for ascites removal by paracentesis and five patients for ascites removal by paracentesis and renal impairment. The median time to first liver-related complication was not significantly longer in the albumin group (20 vs. 7 days). However, the total number of liver-related complications adjusted to a 100-day period was significantly lower in the albumin group. The median hospital cost for a 30-day period was significantly lower in the albumin group (1915 euros vs. 4612 euros).
Conclusions: In patients with cirrhosis and ascites, human albumin appears to be more effective in preventing liver-related complications than synthetic colloid. This may be associated with decreased hospital costs.